<div id="readability-page-1"><div><p>Health-care companies rose as traders bought into the defensive sector ahead of key economic and inflation data.</p><p>    Sanofi shares fell after an experimental treatment for multiple sclerosis was hit by a double setback, with results of a late-stage study missing a key goal and U.S. regulators signaling a decision on the drug would be delayed again. </p><p>    Obesity-drug maker Eli Lilly shares rose by more than 3%, testing all-time highs, amid optimism about demand. </p><p>   Write to Rob Curran at rob.curran@dowjones.com </p><p>    (END) Dow Jones Newswires</p><p>12-15-25 1753ET</p></div></div>

禮來

賽諾菲

賽諾菲集團

<p>醫療保健公司股價上漲，因為交易者在關鍵經濟和通脹數據公佈前買入防禦性行業。賽諾菲的股價下跌，因為其一項針對多發性硬化症的實驗性治療遭遇雙重挫折，晚期研究的結果未能達到關鍵目標，美國監管機構表示該藥物的決定將再次推遲。肥胖藥物製造商禮來的股價上漲超過 3%，測試歷史新高，市場對需求的樂觀情緒推動了股價。請聯繫 Rob Curran，郵箱為 rob.curran@dowjones.com (完) 道瓊斯新聞社 12-15-25 1753ET</p>

由於防禦性偏好，醫療保健板塊上漲——醫療保健綜述